Print

Cyclacel Limited (CYCC) Receives Complaint Filed by Celgene Corporation (CELG) Seeking to Avoid Certain Cyclacel Patents  
5/3/2010 10:22:14 AM

BERKELEY HEIGHTS, N.J., April 30, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid. Cyclacel and its counsel have not had an opportunity to thoroughly review these filings.
//-->